
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush increased their Q2 2026 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, June 30th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $0.23 per share for the quarter, up from their previous forecast of $0.14. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q3 2026 earnings at $0.18 EPS, FY2026 earnings at $0.84 EPS and FY2028 earnings at $0.96 EPS.
A number of other equities research analysts have also recently commented on the company. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Needham & Company LLC reiterated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, June 25th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. upped their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. Finally, Bank of America increased their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, July 1st. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $16.70.
Check Out Our Latest Research Report on BCRX
BioCryst Pharmaceuticals Price Performance
BCRX stock traded down $0.08 during midday trading on Thursday, hitting $8.95. 1,407,127 shares of the stock traded hands, compared to its average volume of 3,039,076. BioCryst Pharmaceuticals has a 1-year low of $6.02 and a 1-year high of $11.31. The stock's fifty day simple moving average is $10.06 and its 200-day simple moving average is $8.61. The firm has a market cap of $1.87 billion, a P/E ratio of -34.40, a PEG ratio of 2.55 and a beta of 1.04.
Institutional Trading of BioCryst Pharmaceuticals
Institutional investors have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $33,000. GAMMA Investing LLC lifted its stake in shares of BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after buying an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC purchased a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at about $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at about $79,000. 85.88% of the stock is owned by institutional investors and hedge funds.
BioCryst Pharmaceuticals Company Profile
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Featured Stories

Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.